[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peanut-allergies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peanut-allergies":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,74,101,123,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100652662","flow-cast-peanut-trial-100652662",false,"NCT07775430","Flow CAST® Peanut Trial","Clinical Evaluation of Flow CAST® as an Aid in the Diagnosis of Peanut Allergy","Inclusion Criteria:\n\n* Individual undergoing a blood draw\n* Individual willing and able to provide two additional tubes of blood (3ml each tube) for research purposes\n* Individual or legal guardian will and able to sign the informed consent form to participate in the study\n\nExclusion Criteria:\n\n* Individual has undergone immunotherapy for peanuts or other identified allergens that have been shown to cause allergic symptoms\n* Individual has been exposed to systemically administered glucocorticoids within the last 24 hours.\n* Individual has been recently exposed to small molecule immunosuppressive medications\n* Individual has been recently exposed to treatment with biologics interfering with the type-I allergic pathway\n* Individual is currently involved in another \"allergy treatment related\" clinical research study",true,"ALL","6 Months",{"count":20,"type":21},245,"ESTIMATED","OBSERVATIONAL","This will be a multi-center, prospective evaluation, conducted at a minimum of four (4) U.S. sites. Sites will enroll peanut allergic subjects, subjects with allergies other than peanut and apparently healthy non-atopic control subjects and collect blood samples for testing using Flow CAST® and the comparative ImmunoCAP sIgE test.",[25],"Peanut Allergies",[27,28,29,30],"Food allergy","peanut allergy","allergy","peanut","NOT_YET_RECRUITING","2026-08-17",{"date":34,"type":35},"2026-08-20","ACTUAL",{"date":37,"type":21},"2026-10-01",{"date":39,"type":21},"2027-12-31",{"name":41,"class":42},"Bühlmann Laboratories AG","INDUSTRY",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100651607","multi-food-oral-immunotherapy-for-peanut-and-tree-nuts-100651607","NCT07764159","Multi-Food Oral Immunotherapy for Peanut and Tree Nuts","An Open-Label, Multicenter, Randomized Clinical Trial Evaluating the Efficacy and Safety of Oral Multi-Food Immunotherapy With Peanut and Tree Nuts Protein Mixtures","Inclusion Criteria:\n\n* Age 1-12 years;\n* Confirmed allergy to at least two allergens included in the protocol, i.e., peanut and\u002For tree nuts: cashew, walnut, hazelnut, and almond;\n* Positive skin prick test (SPT) (wheal diameter ≥ 3 mm) and\u002For specific IgE (sIgE) level \\> 0.35 kUA\u002FL for at least two of the analyzed allergens;\n* Positive OFC-1 (oral food challenge) of grade I-IV according to the WAO classification for at least two allergens, with a positive reaction occurring after administration of a dose ≥ 3 mg and ≤ 3000 mg of allergen protein;\n* Participants may be enrolled based on the abbreviated procedure as outlined in the study description;\n* Written informed consent obtained from a legal guardian, and, where applicable, assent from the child in accordance with their age and level of maturity;\n* Good prognosis for compliance and cooperation of the patient and their caregivers.\n\nExclusion Criteria:\n\n* Allergic reaction at the lowest challenge dose of 1 mg of allergen protein for any allergen, or no allergic reaction after administration of the maximum dose of 3000 mg of allergen protein for at least four of the analyzed allergens;\n* History of anaphylaxis with a grade V reaction according to the WAO classification, either during an oral food challenge or in the patient's medical history;\n* Severe asthma;\n* Poorly controlled asthma according to GINA 2025 (lack of symptom control and\u002For ≥2 exacerbations requiring systemic glucocorticoids or ≥1 exacerbation requiring hospitalization within the last 12 months), or in children able to perform spirometry: FEV1 \\\u003C -1.64 Z-score and\u002For FEV1\u002FFVC \\\u003C -1.64 Z-score;\n* Eosinophilic gastrointestinal disease;\n* Other chronic diseases requiring ongoing treatment which, in the investigator's opinion, may increase the risk associated with study participation or interfere with the interpretation of results, including severe cardiac disease, epilepsy, metabolic disorders, or diabetes;\n* Previous immunotherapy with food allergens;\n* Concurrent immunotherapy with aeroallergens;\n* Treatment with biologic agents, beta-blockers, ACE inhibitors, or calcium channel blockers;\n* Oral corticosteroid therapy meeting any of the following criteria: daily treatment for \\>1 month within the last 12 months; at least two courses lasting ≥7 days within the last 12 months; one course lasting ≥7 days within the last 3 months;\n* Lack of consent to participate in the study or insufficient cooperation of the patient and\u002For caregivers. In such cases, patients will receive standard medical care, including allergen avoidance and provision of emergency medication.\n\nWell-controlled asthma, allergic rhinitis, and atopic dermatitis are not exclusion criteria.","1 Year","12 Years",{"count":53,"type":21},39,"INTERVENTIONAL",[56],"NA","This study aims to evaluate the efficacy and safety of multi-food oral immunotherapy (multi-OIT) using peanut and tree nuts proteins in children with confirmed food allergy to at least two allergens. Participants will be randomized in a 2:1 ratio to receive either multi-OIT or standard management consisting of an elimination diet. The primary objective is to evaluate immunotherapy efficacy defined as achieving tolerance to a cumulative dose of 4444 mg of protein during an oral food challenge (OFC-2) for at least one allergen that elicited a reaction during baseline challenge (OFC-1), compared with the control group. Secondary outcomes include the proportion of participants tolerating multiple allergens at the target cumulative dose; the incidence, type, and severity of adverse events classified according to the World Allergy Organization (WAO) grading system; changes in immunological parameters, including allergen-specific IgE and IgG4 levels; changes in skin prick test responses; changes in the quality of life of patients and their families.",[59,60,25,61,62],"Food Allergies","Food Allergy in Children","Tree Nut Allergies","Oral Immunotherapy for Food Allergy","2026-08-11",{"date":65,"type":35},"2026-08-13",{"date":67,"type":21},"2026-09",{"date":69,"type":21},"2031-12",{"name":71,"class":72},"Medical University of Warsaw","OTHER",4,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":54,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100645720","phase-1-single-ascending-and-multiple-ascending-dose-study-of-lca-0061-100645720","NCT07701954","Single Ascending and Multiple Ascending Dose Study of LCA-0061","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single Doses of LCA-0061 in Atopic Healthy Participants and Multiple Doses of LCA-0061 in Participants With Peanut Allergy","Key Inclusion Criteria: Part A (SAD) and Part B (MAD)\n\n1. Must provide written consent for participation\n2. Have a body mass index (BMI) within the range of 18.0 to 30.0 kg\u002Fm2 (inclusive) and body weight ≥ 50kg at screening\n3. Have elevated serum IgE at screening\n4. Female participants of childbearing potential or male participants capable of fathering a child must be willing to use highly effective methods of contraception throughout the study and for at least 30 days after the last dose of the investigational product.\n\nPart A Only\n\n1.Must be otherwise healthy with history of atopy defined as one or more of the following: history of positive skin tests to common allergens, allergic conjunctivitis, food allergy, atopic dermatitis, urticaria\n\nPart B Only\n\n1. Be otherwise healthy with history of peanut allergy\n2. Elevated peanut-specific serum IgE within 6 months of screening\n3. Have positive skin prick test (SPT) to peanuts at screening\n\nKey Exclusion Criteria: Part A and B\n\n1. Pregnant or lactating\n2. History of clinically relevant underlying comorbidities including:\n\n   1. chronic obstructive pulmonary disease\n   2. myocardial infarction\n   3. chronic heart failure or unstable angina pectoris\n   4. hyperlipidemia\n   5. liver disease or known hepatic or biliary abnormalities \\[except Gilbert's disease or asymptomatic gallstones\\]\n   6. autoimmune or connective tissue disease\n   7. chronic inflammatory disease\n   8. persistent chronic or recurring acute infection requiring treatment with antibiotics, antivirals, or antifungals\n   9. poorly controlled atopic dermatitis requiring treatment with phototherapy, systemic immunosuppressants, or immunomodulators\n   10. Poorly controlled asthma\n   11. poorly controlled hypertension\n3. clinically significant abnormal electrocardiogram or laboratory tests (hematology, clinical chemistries, liver function tests, lipid panel, serology, or urinalysis) at screening\n4. Currently receiving immunotherapy for food allergies\n5. Use of nicotine containing products (excluding nicotine patches or gum for smoking cessation) within 6 months prior to screening.\n6. Positive test for alcohol or illicit drugs at screening or prior to dosing.\n7. Other conditions or concomitant medications that are excluded by the protocol, or in the opinion of the investigator, or sponsor representative, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.","18 Years","55 Years",{"count":84,"type":21},72,[86],"PHASE1","This is a Phase 1combined single ascending dose (SAD)\u002Fmultiple ascending dose (MAD) randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple ascending subcutaneous doses of LCA-0061in participants with atopic conditions (SAD) and participants with peanut allergy (MAD).",[89,25],"Atopic Disease","RECRUITING","2026-07-13",{"date":93,"type":35},"2026-07-14",{"date":95,"type":35},"2026-06-26",{"date":97,"type":21},"2028-04",{"name":99,"class":42},"Lycia Therapeutics, Inc.",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":82,"enrollmentInfo":108,"targetDuration":4,"studyType":54,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100615010","phase-1-study-to-evaluate-the-safety-pharmacokinetic-and-pharmacodynamic-effects-of-my006-in-healthy-volunteers-and-patients-with-peanut-allergy-100615010","NCT07287033","Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy","A Randomized, Quadruple-blinded, Placebo-controlled, Single-ascending and Multiple Dose Study to Evaluate the Safety, Local Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Exploratory Clinical Activity of MY006 in Healthy Volunteers and Adolescent and Adult Patients With Peanut Allergy","Key Inclusion Criteria:\n\nPart A - Single-ascending dose and multiple dose cohorts in healthy volunteers\n\n1. Subject is male or female between 18 to 55 years of age, inclusive, at the screening visit.\n2. Subject agrees voluntarily to participate, and is able to read and understand, and willing to sign, the Institutional Review Board\u002FIndependent Ethics Committee-approved informed consent form prior to performing any screening visit procedures.\n3. Subject weight at screening and admission is between 45 kg and 100 kg, inclusive.\n4. Subject has a body mass index between 18.0 and 30.0 kg\u002Fm2, inclusive, at screening visit.\n\nPart B - Peanut-allergic patient cohorts\n\n1. Participant and\u002For parent\u002Flegal guardian must be able to understand and provide informed consent and\u002For assent, as applicable.\n2. Patient is male or female between 12 to 55 years of age, inclusive, at the screening visit.\n3. Patient weight at screening and admission is between 40 kg and 100 kg, inclusive.\n4. If patient is 12-17 years of age, their body mass index (BMI) must be above the 5th percentile and below the 95th percentile for age and sex at the screening visit. If patient is 18 years of age or above, their BMI must be between 18.0 and 30.0 kg\u002Fm2, inclusive, at the screening visit.\n5. Patient has a history of allergy to peanut and meets all of the following criteria:\n\n   1. Positive skin prick test (≥5 mm wheal greater than Placebo) to peanut; and\n   2. Positive specific IgE (≥0.7 kUA\u002FL) to peanut and Ara h 2 at screening determined by ImmunoCap; and\n   3. Positive double-blinded challenge to peanut during the screening period, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg of peanut protein.\n6. Patient is willing and able to avoid peanut-containing products and any other allergy-inducing foods known to the patient for the duration of study participation.\n\nKey Exclusion Criteria:\n\nPart A - Single-ascending dose and multiple dose cohorts in healthy volunteers\n\n1. Subject has a clinically relevant history, as determined by the Principal Investigator or designee, or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, and\u002For connective tissue diseases or disorders.\n2. Subject has clinically significant abnormal vital signs, after 5 minutes or more of sitting rest, defined as any of the following:\n\n   1. Systolic blood pressure ≥140 mmHg;\n   2. Diastolic blood pressure ≥90 mmHg; and\u002For\n   3. Heart rate ≥90 beats per minute.\n3. Subject has any clinically significant abnormalities in rhythm, conduction, or morphology of the resting electrocardiogram (ECG) and\u002For any clinically significant abnormalities in the 12-lead ECG as considered by the Principal Investigator or designee that may interfere with the interpretation of QTc interval changes.\n4. Subject has history of severe allergy\u002Fhypersensitivity, ongoing clinically significant allergy\u002Fhypersensitivity, as judged by the Principal Investigator or designee, known or suspected allergy to peanuts, and\u002For history of hypersensitivity to drugs with a similar structure or class.\n\nPart B - Peanut-allergy patient cohorts\n\n1. Patient has history of frequent or recent severe, life-threatening episodes of anaphylaxis or anaphylactic shock to peanut, as defined by more than 3 episodes of anaphylaxis within the past year and\u002For an episode of anaphylaxis within 60 days of screening.\n2. Patient has uncontrolled or severe asthma\u002Fwheezing at screening, defined by one or more of the following criteria:\n\n   1. Global Initiative for Asthma criteria regarding asthma control per latest guidelines;\n   2. History of two or more systemic corticosteroid courses within 6 months of screening or one course of systemic corticosteroids within three months of screening to treat asthma\u002Fwheezing;\n   3. Prior intubation\u002Fmechanical ventilation for asthma\u002Fwheezing;\n   4. One hospitalization or emergency department visit for asthma\u002Fwheezing within 12 months of screening;\n   5. Inhaled corticosteroid (ICS) dosing of \\>500 mcg daily fluticasone (or equivalent ICS based on the CoFAR Inhaled Corticosteroid Equivalency Tables); and\u002For\n   6. Forced expiratory volume in one second (FEV1) \\\u003C80% of predicted or FEV1\u002Fforced vital capacity \\\u003C75%, with or without controller medications.\n3. Patient has unstable exacerbated atopic disease (e.g., atopic dermatitis, urticaria, allergic rhinitis) defined by an episode of disease requiring initiation of systemic immunosuppressive or immunomodulatory treatment in the last 3 months.\n4. Patient has current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal, or metabolic dysfunction unless currently controlled and stable as judged by the Principal Investigator.\n5. Patient has abnormal vital signs, after 5 minutes or more of sitting rest, defined as any of the following:\n\n   1. Systolic blood pressure ≥140 mmHg;\n   2. Diastolic blood pressure ≥90 mmHg; and\u002For\n   3. Heart rate ≥90 beats per minute.",{"count":109,"type":21},48,[86],"The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake. In the first part of the study, adult participants receive one dose or two doses of MY006 or a placebo, administered by subcutaneous injection. The safety of MY006, including the number of adverse events, injection-site reactions, and immunogenicity, in these participants will be reviewed by an independent Safety Monitoring Committee and, if the safety is judged acceptable, the second part of the study will be started. In the second part of the study, adult and adolescent participants with peanut allergy receive one dose of MY006 or a placebo, administered by subcutaneous injection. Several weeks later, the participants are given a food peanut challenge to assess reactions and treatment effects. The duration of the study for participants is for up to 32 weeks.",[25],"2026-05-05",{"date":115,"type":35},"2026-05-06",{"date":117,"type":35},"2025-12-06",{"date":119,"type":21},"2027-04",{"name":121,"class":42},"Mabylon AG",2,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":100},"100620558","a-long-term-observational-follow-up-study-of-children-and-young-people-who-underwent-an-18-month-course-of-oral-immunotherapy-treatment-for-peanut-egg-or-milk-allergy-5-15-years-post-treatment-100620558","NCT07359183","A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)","Long Term Outcomes Associated With Attainment of Remission Following Oral Immunotherapy to Peanut, Egg and Cow's Milk (LPEM Study)","LPEM","Inclusion Criteria:\n\n* Previous participant of PEAT, PrEMO, PPOIT-001 or PPOIT-002 parent study\n* Received at least one dose of OIT treatment in the parent study\n* Written informed consent from participant and\u002For parent\u002Fguardian (if below 18 years of age)\n\nExclusion Criteria:\n\n-Have any conditions that, in the opinion of the investigator, precludes participation for reason of safety",{"count":132,"type":21},147,"The goal of this observational study is to learn about the long-term outcomes of children and young people who underwent an 18-month course of oral immunotherapy (OIT) treatment for peanut, egg or milk allergy. It aims to:\n\n• Compare long-term changes in health-related quality of life (HRQL) at 5-15 years after stopping OIT in participants who achieved remission and those who did not.\n\nParticipants will attend a single follow-up visit for:\n\n* A blood test\n* Skin prick test (SPT)\n* Allergy questionnaires",[59,25,135,136],"Egg Allergy","Milk Allergy","2026-01-29",{"date":139,"type":35},"2026-02-02",{"date":141,"type":35},"2026-01-13",{"date":143,"type":21},"2027-01",{"name":145,"class":72},"Murdoch Childrens Research Institute",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":16,"sex":17,"minAge":50,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":100},"100223945","blood-samples-for-the-study-of-peanut-tree-nut-and-other-food-allergies-100223945","NCT02192866","Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies","Inclusion Criteria:\n\nThis protocol is to draw blood for a variety of related studies of food allergy. For this reason, we will list each group of subjects and the inclusion criteria for that group.\n\n1. De-identified sera or plasma from patients who have undergone Oral ImmunoTherapy (OIT) for peanut allergy. These samples already exist.\n\n   * Inclusion criteria:\n\n     1. patients have been enrolled in a controlled trial of OIT for peanuts, and had at least one oral challenge.\n     2. Age 1-75.\n2. De-identified samples from patients who are undergoing clinically indicated food challenges for peanut allergy.\n\n   * Inclusion criteria:\n\n     1. concern regarding possible allergy to peanuts,\n     2. age 1-75,\n     3. plan to undergo a clinically indicated challenge with peanuts.\n3. Patients with peanut allergy.\n\n   * Inclusion criteria:\n\n     1. excellent history of a systemic reaction to peanuts,\n     2. age 6-75.\n4. Patients with other food allergies (especially tree nuts).\n\n   * Inclusion criteria:\n\n     1. excellent history of a systemic reaction to tree nuts or other foods,\n     2. age 6-75.\n5. Normal controls.\n\n   * Inclusion criteria:\n\n     1. no known food allergies,\n     2. recent ingestion of peanuts without difficulty, and\n     3. age 6-75.\n\nExclusion Criteria:\n\n1. Any known significant medical or psychiatric diagnosis\n2. Use of an investigational drug within 30 days\n3. Use of omalizumab (anti-IgE; Xolair) within 6 months","75 Years",{"count":154,"type":21},270,"Food allergies are now a major problem. These experiments involve getting blood from people with food allergies and from people without food allergies. The blood collected will be used to answer questions and find information about peanut and other food allergies.\n\nSamples will come from:\n\n* People signed up by the investigators at the University of Colorado Denver\n* University of North Carolina, Massachusetts General Hospital, Children's Hospital of Colorado and the Immune Tolerance Network (Benaroya Research Institute) where people have been treated for peanut allergies\n* University of North Carolina, Massachusetts General Hospital, National Jewish Health and The Children's Hospital in Denver where people have taken part or will take part in clinically indicated oral food challenges.\n\nBlood and health histories from the University of North Carolina, Massachusetts General Hospital, National Jewish Health, The Children's Hospital and the Immune Tolerance Network will not have personal information linked.\n\nThe specific aims of this experiment are:\n\n1. Come up with a lab test that will predict how bad an allergic reaction will be to peanuts.\n2. Find out what part of a peanut causes allergic reactions.\n3. Come up with preventions that can block peanut allergies.\n4. Find the strongest proteins in walnuts.",[25,61,157],"Other Food Allergies","2022-12-14",{"date":160,"type":35},"2022-12-19",{"date":162,"type":35},"2014-02",{"date":164,"type":21},"2030-12",{"name":166,"class":72},"University of Colorado, Denver"]